Acadia Pharmaceuticals Inc. filings document the regulatory record for a commercial biopharmaceutical company focused on neurological and rare diseases. Recent Form 8-K reports furnish quarterly and annual operating results, product-sales disclosures for NUPLAZID and DAYBUE, corporate presentations and Regulation FD materials, and updates tied to research-and-development leadership.
Proxy and governance filings describe board composition, committee service, director compensation, executive compensation, equity-incentive awards and annual meeting matters. The filings also record board appointments and resignations, non-employee director compensation under equity plans, and other material-event disclosures affecting Acadia’s governance and capital structure.
ACADIA Pharmaceuticals Inc. reported Phase 2 topline results from the RADIANT program evaluating remlifanserin for hallucinations and delusions associated with Alzheimer’s disease psychosis. At week 6, once-daily 60 mg remlifanserin had a change from baseline of -12.6 on SAPS-H+D versus -10.4 for placebo (standardized effect size 0.26; p=0.0603). On the key secondary measure, CGI-S-ADP, the changes were -1.3 versus -0.9 (standardized effect size 0.37; nominal p=0.0077). The difference between 60 mg and placebo increased through the six-week treatment period on both measures.
Acadia described safety findings across both doses as favorable, with adverse-event rates similar to placebo, no signal of QT prolongation versus placebo, and no deaths in the remlifanserin treatment arms. The company plans to continue enrolling in two ongoing Phase 3 studies while amending the program, including removing the 30 mg dose arm. Remlifanserin is also being studied in Phase 2 for Lewy body dementia psychosis.
ACADIA Pharmaceuticals’ EVP and CFO Mark C. Schneyer exercised stock options covering 20,141 shares of common stock at an exercise price of $17.84 per share on August 5–6, 2026.
He then sold 20,141 shares in market transactions at prices around $29 per share under a Rule 10b5-1 trading plan adopted on May 19, 2025.
State Street Corporation has filed as a significant institutional holder of ACADIA PHARMACEUTICALS INC common stock. The filing reports that State Street beneficially owns 9,076,212 shares of common stock, representing 5.3% of the class.
State Street reports no sole voting or dispositive power, but shared voting power over 8,679,785 shares and shared dispositive power over 9,076,212 shares. Subsidiaries involved include SSGA Funds Management, Inc. and several State Street Global Advisors entities, indicating the holdings are managed across affiliated investment advisers.
Acadia Pharmaceuticals reported GAAP total revenues of $308 million for the quarter ended June 30, 2026, up 16% from $265 million a year earlier and 17% versus non-GAAP adjusted revenues. NUPLAZID net sales were $183 million, up 9% year-over-year and 10% on a non-GAAP adjusted basis, while DAYBUE net sales reached $125 million, up 30%. Quarterly net income was $32 million, or $0.18 per diluted share, and cash, cash equivalents and investment securities totaled $956 million.
The company raised its 2026 total revenue guidance to $1.24–$1.30 billion, increased DAYBUE sales guidance to $480–$510 million, and lowered expected R&D expenses to $355–$380 million. Acadia highlighted progress for remlifanserin in Alzheimer’s disease psychosis, including FDA Fast Track designation and ongoing RADIANT Phase 2/3 work, and noted a CHMP positive opinion recommending EU marketing authorization for DAYBU in Rett syndrome.
ACADIA Pharmaceuticals executive Elizabeth H.Z. Thompson, EVP and Head of Research & Development, reported vesting and conversion of 32,272 restricted stock units into common stock on July 29, 2026. To cover withholding taxes on this vesting, she sold 16,558 shares of common stock on July 30, 2026 at prices around $26.13–$26.17 per share in mandatory transactions intended to comply with Rule 10b5-1(c) requirements. The RSU award vests 50% on July 29, 2026 and 25% on each of July 29, 2027 and July 29, 2028.
ACADIA PHARMACEUTICALS principal accounting officer James Kihara sold 11,421 shares of common stock in an open-market transaction at a weighted average price of $26.0846 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025, and Kihara now holds 13,088 shares directly.